Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

• Status: Withdrawn
• Trial end date: 2018-02-13

Summary

In this phase I study, escalating doses of IXAZOMIB will be combined with the POMP/D regimen.

• Phase: Phase 1

Details

• Lead Sponsor: Ehab L Atallah
• Treatments: 6-Mercaptopurine; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Glycine; Ixazomib; Methotrexate; Prednisone; Vincristine